SCHEMBL25417015

SCHEMBL25417015

O=C(O)CCCCCNC(=O)CCCC[C@H]1SC[C@H]2NC(=O)N[C@H]21

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.77
MEN1 O00255 1/20 0.77
ABL1 P00519 1/20 0.77
LMNA P02545 1/20 0.77
PKM P14618 1/20 0.77
IDE P14735 1/20 0.77
MAPK1 P28482 1/20 0.77
KMT2A Q03164 1/20 0.77
RIN1 Q13671 1/20 0.77
L3MBTL1 Q9Y468 1/20 0.77
FOLH1 Q04609 2/20 0.64
CA12 O43570 2/20 0.61
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA9 Q16790 2/20 0.61
PLCD1 P51178 1/20 0.61
CAPN1 P07384 2/20 0.59
HLCS P50747 2/20 0.58
ITGB1 P05556 1/20 0.58
ITGA4 P13612 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10171661 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL565479 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL383254 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL16913029 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL2153169 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL3143245 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL1270494 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL18257230 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL22975316 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM
SCHEMBL565248 1.00 TDP1 (0.77) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230288426-A1 REAGENT FOR MEASURING L-BIOTIN, METHOD FOR MEASURING SAMPLE CONTAINING L-BIOTIN, METHOD FOR DETERMINING NUMBER OF LABELS OF L-BIOTIN-LABELED SUBSTANCE, AND METHOD FOR PRODUCING SOLID PHASE ON WHICH OPTICALLY ISOMERIC BIOTIN-BINDING SITE IS IMMOBILIZED SYSMEX CORPORATION (JP) 2023-09-14 US disclosed
US-20230288426-A1 REAGENT FOR MEASURING L-BIOTIN, METHOD FOR MEASURING SAMPLE CONTAINING L-BIOTIN, METHOD FOR DETERMINING NUMBER OF LABELS OF L-BIOTIN-LABELED SUBSTANCE, AND METHOD FOR PRODUCING SOLID PHASE ON WHICH OPTICALLY ISOMERIC BIOTIN-BINDING SITE IS IMMOBILIZED SYSMEX CORPORATION (JP) 2023-09-14 US disclosed
US-20230288411-A1 POLYPEPTIDE, MULTIMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT SYSMEX CORPORATION (JP) 2023-09-14 US disclosed
US-20230288411-A1 POLYPEPTIDE, MULTIMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT SYSMEX CORPORATION (JP) 2023-09-14 US disclosed
US-20230288411-A1 POLYPEPTIDE, MULTIMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT SYSMEX CORPORATION (JP) 2023-09-14 US disclosed
EP-4242660-A1 REAGENT FOR MEASURING L-BIOTIN, METHOD FOR MEASURING SAMPLE CONTAINING L-BIOTIN, METHOD FOR DETERMINING NUMBER OF LABELS OF L-BIOTIN-LABELED SUBSTANCE, AND METHOD FOR PRODUCING SOLID PHASE ON WHICH OPTICALLY ISOMERIC BIOTIN-BINDING SITE IS IMMOBILIZED SYSMEX CORPORATION (JP) 2023-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230288426-A1 REAGENT FOR MEASURING L-BIOTIN, METHOD FOR MEASURING SAMPLE CONTAINING L-BIOTIN, METHOD FOR DETERMINING NUMBER OF LABELS OF L-BIOTIN-LABELED SUBSTANCE, AND METHOD FOR PRODUCING SOLID PHASE ON WHICH OPTICALLY ISOMERIC BIOTIN-BINDING SITE IS IMMOBILIZED HLCS, BDKRB1, BTD TDP1 4724/4885MEN1 2359/4885ABL1 2387/4885
US-20230288411-A1 POLYPEPTIDE, MULTIMER, SOLID PHASE, MEASUREMENT METHOD FOR TEST SUBSTANCE, AND REAGENT KIT BTD, DNPEP, GC TDP1 2801/4885MEN1 1271/4885ABL1 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.